The latest shared research on American Society of Clinical Oncology
Conference Insight: Datamonitor’s Analysis of The American Society of Clinical Oncology Annual Meeting 2011
Datamonitor attended the 47th meeting of the American Society of Clinical Oncology (ASCO) which took place between June 3 and June 7, 2011, in Chicago, Illinois. The theme of this year’s conference was “patients, pathways, progress,” highlighting the growing trend towards personalized medicine in cancer care and the importance of targeting the distinct pathways in cancer cells driving growth, invasion, and metastases. Datamonitor has identified the following key highlightsfrom the meeting: Roche/Genentech's and Plexxikon’s vemurafenib and Bristol-Myers Squibb’s Yervoy (ipilimumab) are the first drugs in decades to extend overall survival as first-line treatments for advanced melanoma. Avastin (bevacizumab; Genentech/Roche/Chugai) showed improvements in progression-free survival in a ...
